{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477315023
| image = 
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = F(ab')2
| source = zu/o
| target = [[VEGFR2]]
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 934216-54-3
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}
'''Alacizumab pegol''' is an [[antineoplastic]] agent. Chemically, it is a [[pegylated]] [[F(ab')2|F(ab')<sub>2</sub> fragment]] of a [[monoclonal antibodies|monoclonal antibody]].<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], ''World Health Organization''.</ref>

== References ==
<references/>

{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}
{{Growth factor receptor modulators}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}